From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
news
Approximately 30% of all breast cancers currently diagnosed have a genetic abnormality
Today, we know much more about why a cell becomes cancerous and about which proteins and genes are responsible for this happening
The Vall d’Hebron Institute of Oncology (VHIO) has published a new study describing a new molecular mechanism that regulates the renewal of the glioma stem cells. The findings represent an important advancement in the research centred on one of the most aggressive brain tumours, the glioblastoma multiforme
Davide Melisi will offer a conference about TGF-ß signaling for anticancer therapies
Christopher Proud, from Southampton University, presents the latest advancements related to mTOR, involved in certain cancers
Antonio Hurtado, from the Cambridge Research Institute, will offer a seminar on the factors that cause resistance to Tamoxifen on breast cancer patients
It is the first National Agreement that includes the Academic environment, basic research, clinical research and the pharmaceutical industry
The “Olga Torres” Foundation awards to a VHIO research group a grant for the research on tumor stem cells
Arkaitz Carracedo, from the Harvard Medical School, gives a lecture on the latest developments on potential therapy for cancer
